| Material . | Method . | Study summary . | Reference . |
|---|---|---|---|
| primary tissues, cell lines | RNA/protein | GHR overexpressed in neoplastic than normal prostate | (265) |
| cells and patient samples | GHR expression | readily detectable expression, increases proliferation | (275) |
| primary tissues, cell lines | GH treatment | acute increase in prostatic androgen receptor | (265) |
| cell lines | GH treatment | increases IGF1 and IGF1R differentially based in androgen-dependent manner | (268) |
| tumor-prone C3(1)-Tag mice | crossed with GHRKO mice | progeny have highly reduced tumor incidence, burden, and volume, reduced proliferation, increased apoptosis | (269) |
| tumor-prone C3(1)-Tag mice | prostate-specific inducible GHRKO mice | progeny have reduced tumor incidence, burden, reduced proliferation, increased apoptosis | (270) |
| mouse tumor cell lines in nude mice | GHR overexpression | increased xenograft size and weight | (270) |
| PTEN-null CRC cells in nude mice | GHRA (pegvisomant) treatment, RNA-seq | suppressed tumor growth, several DEGs | (274) |
| tumor-prone Probasin/Tag rat | crossed with SDR | progeny has markedly reduced tumor incidence | (272) |
| Material . | Method . | Study summary . | Reference . |
|---|---|---|---|
| primary tissues, cell lines | RNA/protein | GHR overexpressed in neoplastic than normal prostate | (265) |
| cells and patient samples | GHR expression | readily detectable expression, increases proliferation | (275) |
| primary tissues, cell lines | GH treatment | acute increase in prostatic androgen receptor | (265) |
| cell lines | GH treatment | increases IGF1 and IGF1R differentially based in androgen-dependent manner | (268) |
| tumor-prone C3(1)-Tag mice | crossed with GHRKO mice | progeny have highly reduced tumor incidence, burden, and volume, reduced proliferation, increased apoptosis | (269) |
| tumor-prone C3(1)-Tag mice | prostate-specific inducible GHRKO mice | progeny have reduced tumor incidence, burden, reduced proliferation, increased apoptosis | (270) |
| mouse tumor cell lines in nude mice | GHR overexpression | increased xenograft size and weight | (270) |
| PTEN-null CRC cells in nude mice | GHRA (pegvisomant) treatment, RNA-seq | suppressed tumor growth, several DEGs | (274) |
| tumor-prone Probasin/Tag rat | crossed with SDR | progeny has markedly reduced tumor incidence | (272) |
Abbreviations: GH, growth hormone; GHR, growth hormone receptor; GHRA, growth hormone receptor antagonist; SDR, Sprague Dawley rats.
| Material . | Method . | Study summary . | Reference . |
|---|---|---|---|
| primary tissues, cell lines | RNA/protein | GHR overexpressed in neoplastic than normal prostate | (265) |
| cells and patient samples | GHR expression | readily detectable expression, increases proliferation | (275) |
| primary tissues, cell lines | GH treatment | acute increase in prostatic androgen receptor | (265) |
| cell lines | GH treatment | increases IGF1 and IGF1R differentially based in androgen-dependent manner | (268) |
| tumor-prone C3(1)-Tag mice | crossed with GHRKO mice | progeny have highly reduced tumor incidence, burden, and volume, reduced proliferation, increased apoptosis | (269) |
| tumor-prone C3(1)-Tag mice | prostate-specific inducible GHRKO mice | progeny have reduced tumor incidence, burden, reduced proliferation, increased apoptosis | (270) |
| mouse tumor cell lines in nude mice | GHR overexpression | increased xenograft size and weight | (270) |
| PTEN-null CRC cells in nude mice | GHRA (pegvisomant) treatment, RNA-seq | suppressed tumor growth, several DEGs | (274) |
| tumor-prone Probasin/Tag rat | crossed with SDR | progeny has markedly reduced tumor incidence | (272) |
| Material . | Method . | Study summary . | Reference . |
|---|---|---|---|
| primary tissues, cell lines | RNA/protein | GHR overexpressed in neoplastic than normal prostate | (265) |
| cells and patient samples | GHR expression | readily detectable expression, increases proliferation | (275) |
| primary tissues, cell lines | GH treatment | acute increase in prostatic androgen receptor | (265) |
| cell lines | GH treatment | increases IGF1 and IGF1R differentially based in androgen-dependent manner | (268) |
| tumor-prone C3(1)-Tag mice | crossed with GHRKO mice | progeny have highly reduced tumor incidence, burden, and volume, reduced proliferation, increased apoptosis | (269) |
| tumor-prone C3(1)-Tag mice | prostate-specific inducible GHRKO mice | progeny have reduced tumor incidence, burden, reduced proliferation, increased apoptosis | (270) |
| mouse tumor cell lines in nude mice | GHR overexpression | increased xenograft size and weight | (270) |
| PTEN-null CRC cells in nude mice | GHRA (pegvisomant) treatment, RNA-seq | suppressed tumor growth, several DEGs | (274) |
| tumor-prone Probasin/Tag rat | crossed with SDR | progeny has markedly reduced tumor incidence | (272) |
Abbreviations: GH, growth hormone; GHR, growth hormone receptor; GHRA, growth hormone receptor antagonist; SDR, Sprague Dawley rats.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
